VERA Vera Therapeutics Inc - Ordinary Shares - Class A

$VERA -70% underperformance YTD compared to XBI. Serious games here, volume low - this is when I think about a starter.

$VERA Bids on Puts Oct - Dec 25 and below virtually non-existent. Maybe this means something. Hopefully we are nearing a short-term bottom... I do hope

$VERA Fishiest price action in all of quality bio right now. Green candles, strange red to green moves, high volume.

$VERA Yesterday I bot the March 35/40 call debit spread for .95. Seems like a good trade.

$VERA Not that I follow the analyst, but the avg analyst PTs are in the 70s. And, this is below 30 with Institutionals owning most of the shares.

$VERA This probably rallies after October options exp in anticipation of "Kidney Week" presentations. (At least I am hoping so.)

$VERA how many of yall degens think this will get bought out? Drop your guess as to when and how much per share……. GOOO

$VERA No, not at all. Sefaxersen would compete with Fabhalta and Tarpeyo only. They take care of inflammation but do nothing on the root cause. All biotech is dropping because of the rates, that's why.

$VERA Phase II ongoing for a monthly dose option. That will be yet another game changer for Vera for those who would prefer monthly injections, furthering their ability to cut into Novartis and Otsuka's market share with a superior product.

$VERA a $2 dividend would cost shorty $34.5M and would get us out of a rut. Would be a good use of $144 mil of company coffers. They know most of us will reinvest, esp hedgies. I just want to see it at fair value and let the launch dictate the rest. This short bs is ridiculous.

$VERA Watching here. Short the launch games. Can end soon, can go on for a very long time.

Textbook biotech week. $VERA lands an FDA approval for Trutakna in IgA nephropathy on real Phase 3 data and the stock still cannot catch a bid. Down roughly 43 percent this year with an approval in hand. When the sector is this heavy, good news is just liquidity for sellers. That is the tape we are in.

📅 CATALYST REMINDER | $VERA October 22 & 24, 2026 — Clinical Data Presentations October 22: atacicept ORIGIN 3 final efficacy analysis. October 24: interim Phase 2 PIONEER findings. Both are scheduled for ASN Kidney Week. More details in our hub. #VERA #Biotech #ClinicalData

$VERA is this an indication share price is bound for a rebound towards $35. Am I reading this correctly?

$VERA Vera therapeutics announces origin 3 final efficacy analysis of trutakna™ (atacicept-vymj) in iga nephropathy will be a featured late-breaking oral presentation at the opening plenary session of asn kidney week 2026

$VERA looks like someone covered. Not sure why the price action is flat-ish. Could be better, could be worse 🤷‍♂️

$VERA umm, how is it possible u dont know sht about spec bios despite only posting on sepc bios🤔😆 $kod

$VERA Honestly, this price is starting to get ridiculous. If it drops below $30, I’ll average down again, since my current average is $33.